Haleon (HLN) EBT Margin (2021 - 2025)

Haleon's (HLN) quarterly EBT Margin came in at 19.62% in Q4 2025, up 15.01% on a QoQ basis from 17.06% in Q4 2023.

Haleon (HLN) EBT Margin (2021 - 2025) Analysis & Trends

Haleon (HLN) has 4 years of EBT Margin data on file, last reported at 19.62% in Q4 2025.

Quarterly EBT Margin changed N/A year-over-year to 19.62% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 17.71% (changed N/A YoY) and the FY2025 annual result came in at 19.51%, up 251.0% from the prior year.
EBT Margin improved to 19.62% in Q4 2025, from 17.06% in the prior quarter.
In the past five years, EBT Margin ranged from a high of 51.73% in Q4 2022 to a low of 15.19% in Q2 2023.
A 4-year average of 23.22% and a median of 17.87% in 2021 frame the typical range for EBT Margin.
Annual changes were most pronounced in 2022 — EBT Margin jumped 3414 bps — and 2023, when it tumbled 3467 bps.
Tracing HLN's EBT Margin over 4 years: stood at 17.59% in 2021, then soared by 194 bps to 51.73% in 2022, then slumped by 67 bps to 17.06% in 2023, then increased by 15 bps to 19.62% in 2025.
The last three EBT Margin figures came in at 19.62% (Q4 2025), 17.06% (Q4 2023), and 15.19% (Q2 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Haleon	43.89 Bn	42.93 Bn	-	-
2	Teva Pharmaceutical Industries	43.01 Bn	39.35 Bn	2.15 Bn	-10.99%
3	Zoetis	31.52 Bn	29.84 Bn	1.05 Bn	35.09%
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	13.34%
5	United Therapeutics	22.17 Bn	19.51 Bn	683.80 Mn	47.58%
6	Viatris	18.73 Bn	17.85 Bn	1.46 Bn	-1.70%
7	Neurocrine Biosciences	15.51 Bn	15.12 Bn	935.80 Mn	16.91%
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	4.09%
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-	-
10	Alkermes	8.12 Bn	7.46 Bn	397.90 Mn	-0.38%

Download Data